Timolol maleate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318874

CAS#: 26921-17-5 (maleate)

Description: Timolol is a non-selective beta-adrenergic receptor antagonist indicated for treating glaucoma, heart attacks, hypertension, and migraine headache. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, betaadrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.


Chemical Structure

img
Timolol maleate
CAS# 26921-17-5 (maleate)

Theoretical Analysis

MedKoo Cat#: 318874
Name: Timolol maleate
CAS#: 26921-17-5 (maleate)
Chemical Formula: C17H28N4O7S
Exact Mass:
Molecular Weight: 432.492
Elemental Analysis: C, 47.21; H, 6.53; N, 12.95; O, 25.89; S, 7.41

Price and Availability

Size Price Availability Quantity
100.0mg USD 550.0 2 Weeks
200.0mg USD 750.0 2 Weeks
500.0mg USD 1050.0 2 Weeks
1.0g USD 1750.0 2 Weeks
2.0g USD 2250.0 2 Weeks
5.0g USD 4250.0 2 Weeks
Bulk inquiry

Related CAS #: 26921-17-5 (maleate)   26839-75-8 (free base)  

Synonym: L 714,465; L-714,465; L714,465; MK 950; MK-950; MK950; Optimol; Timacar; Timolol maleate; brand name: Betimol, Blocadren, Istalol, Timoptic, Timoptic-XE, Timoptic OcuDose.

IUPAC/Chemical Name: (S)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol maleate

InChi Key: WLRMANUAADYWEA-NWASOUNVSA-N

InChi Code: InChI=1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1

SMILES Code: CC(C)(NC[C@H](O)COC1=NSN=C1N2CCOCC2)C.O=C(O)/C=C\C(O)=O

Appearance: White to off-white crystalline powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 432.492 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fang Y, Ling Z, Sun X. Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol. Drug Des Devel Ther. 2015 May 13;9:2617-25. doi: 10.2147/DDDT.S80338. eCollection 2015. Review. PubMed PMID: 25999695; PubMed Central PMCID: PMC4435054.

2: Radcliffe NM. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014 Dec 12;8:2541-9. doi: 10.2147/OPTH.S76053. eCollection 2014. Review. PubMed PMID: 25540579; PubMed Central PMCID: PMC4270356.

3: Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014 Oct;15(15):2255-62. doi: 10.1517/14656566.2014.955471. Epub 2014 Aug 29. Review. Erratum in: Expert Opin Pharmacother. 2014 Nov;15(16):2473. PubMed PMID: 25170534.

4: Borgman CJ. Topical timolol in the treatment of monocular oscillopsia secondary to superior oblique myokymia: a review. J Optom. 2014 Apr-Jun;7(2):68-74. doi: 10.1016/j.optom.2013.06.004. Epub 2013 Aug 2. Review. PubMed PMID: 24766862; PubMed Central PMCID: PMC4009467.

5: Lou H, Zong Y, Ge YR, Cheng JW, Wei RL. Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. Curr Med Res Opin. 2014 Jul;30(7):1367-73. doi: 10.1185/03007995.2014.905825. Epub 2014 Mar 27. Review. PubMed PMID: 24641069.

6: Chernoff KA, Zippin JH. Allergic contact dermatitis to timolol: a report of 2 cases and review of the literature. Dermatitis. 2014 Jan-Feb;25(1):41-2. doi: 10.1097/DER.0000000000000006. Review. PubMed PMID: 24407055.

7: He M, Wang W, Huang W. Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLoS One. 2013 Dec 11;8(12):e83606. doi: 10.1371/journal.pone.0083606. eCollection 2013. Review. PubMed PMID: 24349536; PubMed Central PMCID: PMC3859645.

8: Lubahn JG, Lee RK, Karp CL. Resolution of conjunctival sessile hemangioma with topical timolol. Cornea. 2014 Jan;33(1):99-100. doi: 10.1097/ICO.0000000000000022. Review. PubMed PMID: 24270678; PubMed Central PMCID: PMC3895456.

9: Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131-5. doi: 10.2147/OPTH.S41358. Epub 2013 Oct 30. Review. PubMed PMID: 24204115; PubMed Central PMCID: PMC3817055.

10: Konstas AG, Mocan MC, Katsanos A, Voudouragkaki IC, Irkec M. Latanoprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Pharmacother. 2013 Sep;14(13):1815-27. doi: 10.1517/14656566.2013.813482. Epub 2013 Jun 28. Review. PubMed PMID: 23806084.

11: Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, Floriani I. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013 May;29(4):382-9. doi: 10.1089/jop.2012.0186. Epub 2012 Dec 11. Review. PubMed PMID: 23231442.

12: Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079. doi: 10.1371/journal.pone.0045079. Epub 2012 Sep 13. Review. PubMed PMID: 23028770; PubMed Central PMCID: PMC3441590.

13: Konstas AG, Quaranta L, Realini T. Overview of the [corrected] travoprost /timolol BAK-free fixed combination. Expert Opin Pharmacother. 2012 Apr;13(5):757-66. doi: 10.1517/14656566.2012.662485. Epub 2012 Feb 24. Review. Erratum in: Expert Opin Pharmacother. 2012 Jun;13(8):1221. PubMed PMID: 22360540.

14: Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011 Oct;27(10):1949-58. doi: 10.1185/03007995.2011.613923. Epub 2011 Aug 31. Review. PubMed PMID: 21878000.

15: Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303. doi: 10.1111/j.1742-7843.2011.00694.x. Review. PubMed PMID: 21385322.

16: Denis P. Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review. Expert Opin Pharmacother. 2011 Feb;12(3):463-71. doi: 10.1517/14656566.2011.551007. Review. PubMed PMID: 21254951.

17: Januleviciene I. Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma. Curr Med Res Opin. 2010 Nov;26(11):2575-8. doi: 10.1185/03007995.2010.517718. Epub 2010 Sep 27. Review. PubMed PMID: 20868340.

18: Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother. 2010 Apr;11(6):959-68. doi: 10.1517/14656561003667540. Review. PubMed PMID: 20307220.

19: Holló G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2009 Aug;10(12):2015-24. doi: 10.1517/14656560903124388. Review. PubMed PMID: 19618994.

20: Vinuesa-Silva JM, Vinuesa-Silva I, Pinazo-Durán MD, Soto-Alvarez J, Delgado-Ortega L, Díaz-Cerezo S. [Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials]. Arch Soc Esp Oftalmol. 2009 Apr;84(4):199-207. Review. Spanish. PubMed PMID: 19384760.



Additional Information

Related CAS#
CAS#26921-17-5 (Timolo maleate).
CAS#26839-75-8 (Timolo free base).